Hyperforin inhibits cancer invasion and metastasis

Cancer Res. 2004 Sep 1;64(17):6225-32. doi: 10.1158/0008-5472.CAN-04-0280.

Abstract

Hyperforin (Hyp), the major lipophilic constituent of St. John's wort, was assayed as a stable dicyclohexylammonium salt (Hyp-DCHA) for cytotoxicity and inhibition of matrix proteinases, tumor invasion, and metastasis. Hyp-DCHA triggered apoptosis-associated cytotoxic effect in both murine (C-26, B16-LU8, and TRAMP-C1) and human (HT-1080 and SK-N-BE) tumor cells; its effect varied, with B16-LU8, HT-1080, and C-26 the most sensitive (IC50 = 5 to 8 micromol/L). At these concentrations, a marked and progressive decline of growth was observed in HT-1080 cells, whereas untransformed endothelial cells were only marginally affected. Hyp-DCHA inhibited in a dose-dependent and noncompetitive manner various proteinases instrumental to extracellular matrix degradation; the activity of leukocyte elastase was inhibited the most (IC50 = 3 micromol/L), followed by cathepsin G and urokinase-type plasminogen activator, whereas that of the matrix metalloproteinases (MMPs) 2 and 9 showed an IC50 > 100 micromol/L. Nevertheless, inhibition of extracellular signal-regulated kinase 1/2 constitutive activity and reduction of MMP-2 and MMP-9 secretion was triggered by 0.5 micromol/L Hyp-DCHA to various degrees in different cell lines, the most in C-26. Inhibition of C-26 and HT-1080 cell chemoinvasion (80 and 54%, respectively) through reconstituted basement membrane was observed at these doses. Finally, in mice that received i.v. injections of C-26 or B16-LU8 cells, daily i.p. administration of Hyp-DCHA-without reaching tumor-cytotoxic blood levels-remarkably reduced inflammatory infiltration, neovascularization, lung weight (-48%), and size of experimental metastases with C-26 (-38%) and number of lung metastases with B16-LU8 (-22%), with preservation of apparently healthy and active behavior. These observations qualify Hyp-DCHA as an interesting lead compound to prevent and contrast cancer spread and metastatic growth.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology
  • Animals
  • Apoptosis / drug effects
  • Bridged Bicyclo Compounds
  • Cell Division / drug effects
  • Cell Survival / drug effects
  • Colonic Neoplasms / blood
  • Colonic Neoplasms / drug therapy
  • Colonic Neoplasms / pathology
  • Cyclohexylamines / blood
  • Cyclohexylamines / pharmacology
  • Enzyme Activation / drug effects
  • Fibrosarcoma / blood
  • Fibrosarcoma / drug therapy
  • Fibrosarcoma / pathology
  • Gelatinases / biosynthesis
  • Humans
  • Lung Neoplasms / blood
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Male
  • Melanoma, Experimental / blood
  • Melanoma, Experimental / drug therapy
  • Melanoma, Experimental / pathology
  • Mice
  • Mice, Inbred BALB C
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases / metabolism
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Neoplasms / blood
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Neuroblastoma / blood
  • Neuroblastoma / drug therapy
  • Neuroblastoma / pathology
  • Phloroglucinol / analogs & derivatives
  • Quaternary Ammonium Compounds / blood
  • Quaternary Ammonium Compounds / pharmacology
  • Serine Endopeptidases / metabolism
  • Terpenes / blood
  • Terpenes / pharmacology*

Substances

  • Bridged Bicyclo Compounds
  • Cyclohexylamines
  • Quaternary Ammonium Compounds
  • Terpenes
  • dicyclohexylamine
  • Phloroglucinol
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • Serine Endopeptidases
  • Gelatinases
  • hyperforin